Cytokinetics, Incorporated

CYTK

US23282W6057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:01 2024-04-23 pm EDT			5-day change	1st Jan Change
65.57 ^USD	-1.09%		-4.97%	-21.46%

Apr. 09	Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	MT
Apr. 05	Sector Update: Health Care Stocks Rise Friday Afternoon	MT

CYTOKINETICS INC : Other Events, Financial Statements and Exhibits (form 8-K)

September 01, 2021 at 04:02 pm EDT

Item 8.01. Other Events.

On September 1, 2021, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

99.1 Press Release dated September 1, 2021 104 Cover Page Interactive Data File (embedded within the Inline XBRL


            document)

Latest news about Cytokinetics, Incorporated

Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	Apr. 09	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 05	MT
Cytokinetics Reports Positive Follow-On Data for Prospective Heart Medication; Shares Rise	Apr. 05	MT
Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session	Apr. 05	CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400 - Biotechnology	Mar. 17	CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400 Health Care	Mar. 17	CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400	Mar. 17	CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) dropped from S&P 600	Mar. 17	CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) dropped from S&P 600 Health Care	Mar. 17	CI
Transcript : Cytokinetics, Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM	Mar. 13
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating	Mar. 06	MT
Transcript : Cytokinetics, Incorporated, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Cytokinetics Q4 Net Loss Narrows, Revenue Decreases; 2024 Outlook Issued	Feb. 27	MT
Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Reports Q4 Revenue $1.7M, vs. Street Est of $13.3M	Feb. 27	MT
Cytokinetics, Incorporated Provides Revenue Guidance for 2024	Feb. 27	CI
Cytokinetics, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Cytokinetics, Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Cytokinetics Insider Sold Shares Worth $960,625, According to a Recent SEC Filing	Feb. 13	MT
Cytokinetics Insider Sold Shares Worth $2,585,497, According to a Recent SEC Filing	Feb. 06	MT
Cytokinetics Insider Sold Shares Worth $994,625, According to a Recent SEC Filing	Feb. 02	MT
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024	Feb. 02	CI
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024	Feb. 02	CI
Cytokinetics Reports 'Favorable Effects' of Aficamten in Hypertrophic Cardiomyopathy Trial	Jan. 25	MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61	Jan. 24	MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating	Jan. 19	MT

Chart Cytokinetics, Incorporated

Duration

Period

More charts

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Cytokinetics, Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

66.29 USD

Average target price

91.34 USD

Spread / Average Target

+37.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYTOKINETICS, INCORPORATED	-21.46%	6.95B
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	103B
REGENERON PHARMACEUTICALS, INC.	+3.31%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.16%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-22.87%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.98B

Bio Therapeutic Drugs

Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Biotechnology & Medical Research

CYTOKINETICS INC : Other Events, Financial Statements and Exhibits (form 8-K)

Latest news about Cytokinetics, Incorporated

Chart Cytokinetics, Incorporated

Company Profile

Income Statement Evolution

Ratings for Cytokinetics, Incorporated

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs